Efor Accelerates Its International Expansion with Two Acquisitions: No deviation & DynamixE

We’re accelerating our international expansion with two simultaneous acquisitions: DynamixE in the United States and No deviation in Singapore. These transactions strengthen our presence in the two most decisive markets of the global pharmaceutical industry and reinforce our role as a trusted industrial partner to the global Top 20 pharma, biotech, and medtech companies. With more than 3,000 employees across 18 countries and €340 million in revenue in 2025, we continue to pursue our ambition of becoming a global leader in quality and compliance for the healthcare industries.